Step Pharma
PrivateLast Round
Grant
Feb 19, 2026
Total Funding Raised
$108.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Step Pharma operates in Healthcare & Life Sciences and is based in Saint-Genis-Pouilly. Its latest recorded funding round was a Grant round in February 2026.
Step Pharma is a biotechnology company that develops proprietary small molecule therapeutics designed for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Step Pharma Comparables
Compare Step Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alethio Therapeutics | 75% | |
| Jabez Biosciences, Inc. | 75% | |
| Trethera Corporation | 74% |
For institutional investors. Book with your work email.
Step Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 19, 2026 | ||||
| Series C | Oct 15, 2025 | ||||
| Series B | Mar 24, 2021 | ||||
| Series A | Nov 21, 2017 | ||||
| Seed | Jul 30, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Step Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Idinvest Partners | Seed, Series A |
| Inserm Transfert | Seed, Series A, Series C |
| Pontifax Venture Capital | Series B, Series A, Series C |
| Institut Imagine | Seed, Series A |
| V-Bio Ventures | Series C |
| Hadean Ventures | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 19, 2026
Secured $2.72M in grant funding.
- Oct 28, 2025
Dr. Karen Smith appointed as the new Chief Medical Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Step Pharma is to present first preliminary data from its ongoing phase 2 VECTRA trial of dencatistat for high-risk essential thrombocythaemia at the 68th ASH Annual Meeting in Louisiana in Dec '26.
For institutional investors. Book with your work email.
Step Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Step Pharma's valuation, stock price, and market status.
Is Step Pharma a public or private company?
Step Pharma is a private company.
What is the current stock price of Step Pharma?
Step Pharma is a private company, so its shares have no public market price. Caplight tracks Step Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Step Pharma worth (valuation)?
Valuation information for Step Pharma is not publicly available.
Can I buy Step Pharma stock?
Step Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Step Pharma's last funding round?
Step Pharma's most recent funding round was Grant on February 19, 2026.
Who are the main investors in Step Pharma?
Key investors in Step Pharma include V-Bio Ventures, Hadean Ventures, Sunstone Life Science Ventures, Kurma Partners.
Will Step Pharma IPO soon?
No public IPO plans have been announced for Step Pharma.
How can I track Step Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Step Pharma's shares on secondary markets.